Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Dual ACE/NEP inhibitors from ADIR

Sep. 27, 1996

Mitsui's Na+/H+-exchange inhibitors for cardiovascular disorders

Sep. 27, 1996

Bristol-Myers Squibb continues to search for new ET antagonists

Sep. 27, 1996

Calcium-antagonist effects of estrogen

Sep. 20, 1996

PLC Systems can halt randomization to medical therapy in TMR trial

Sep. 20, 1996

AMI and magnesium supplementation

Sep. 20, 1996

Use of bisaramil in oxidative stress-related conditions

Sep. 20, 1996

Valaciclovir for restenosis

Sep. 20, 1996

Renin inhibitors in cardiovascular disease

Sep. 20, 1996

Zambon's ACE/NEP inhibitors for cardiovascular indications

Sep. 20, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...